Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Closes $7.7M Acquisition of Spectral Diagnostics Cardiac Test Business

NEW YORK, Feb. 7 (GenomeWeb News) - Nanogen today said it has closed its acquisition of Spectral Diagnostics' rapid cardiac immunoassay test business, originally announced in December.

 

Total cost for the deal was CDN$9 million ($7.7 million), comprising CDN$5.65 million in cash and CDN$3.35 million in Nanogen common shares, Nanogen said.

 

Nanogen will now assume sales, marketing, and manufacturing activities for the Cardiac Status, Decision Point, and i-Lynx reader product lines.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.